hec113995pa
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started May 31, 2019 (NCT03943251)
Timeline
Indications
Mechanism of action
- Dopamine D5 receptorINHIBITOR
DRD5 inhibitor
- Dopamine D3 receptorINHIBITOR
DRD3 inhibitor
- Dopamine D2 receptorINHIBITOR
DRD2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04984512 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2021 | Sunshine Lake Pharma Co., Ltd. |
| NCT04623814 | Phase 1 | Mar 30, 2020 | Sunshine Lake Pharma Co., Ltd. |
| NCT04591301 | Phase 1 | Jul 4, 2019 | Sunshine Lake Pharma Co., Ltd. |
| NCT03943251 | Phase 1 | May 31, 2019 | Sunshine Lake Pharma Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1